For the quarter ending 2025-12-31, PLUR made $198K in revenue. -$6,543K in net income. Net profit margin of -3304.55%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 198 | 316 | 337 | 326 |
| Cost of revenues | 112 | 201 | 185 | 126 |
| Gross profit | 86 | 115 | 151 | 200 |
| Research and development expenses | 3,949 | 3,961 | 3,537 | 3,392 |
| Less participation by the national institute of allergy and infectious diseases, or niaid, the israeli innovation authority, or iia, and horizon europe | 123 | 30 | 217 | 503 |
| Research and development expenses, net | 3,826 | 3,931 | 3,321 | 2,889 |
| General and administrative expenses | 2,766 | 2,534 | 2,490 | 2,509 |
| Operating loss | -6,506 | -6,350 | -5,659 | -5,198 |
| Financial income (expenses), net | - | - | -51 | - |
| Other financial income (expenses), net | -143 | 439 | - | -621 |
| Interest expenses | 231 | 229 | 409 | 217 |
| Total financial income (expenses), net | -374 | 210 | -80 | -838 |
| Loss before taxes | -6,880 | -6,140 | -5,814 | - |
| Tax benefit | -8 | -8 | -1 | - |
| Net loss | -6,872 | -6,132 | -5,738 | -6,036 |
| Net loss attributed to non-controlling interest | -329 | -282 | -171 | -154 |
| Net loss attributed to shareholders | -6,543 | -5,850 | -5,567 | -5,882 |
| Basic net loss per share (in dollars per share) | -0.71 | -0.65 | -0.827 | -1.08 |
| Diluted net loss per share (in dollars per share) | -0.71 | -0.65 | -0.827 | -1.08 |
| Weighted average number of shares used in computing basic net loss per share (in shares) | 9,260,439 | 8,995,635 | 292,585.667 | 5,459,236 |
| Weighted average number of shares used in computing diluted net loss per share (in shares) | 9,260,439 | 8,995,635 | 292,585.667 | 5,459,236 |
Pluri Inc. (PLUR)
Pluri Inc. (PLUR)